Saber, M.M.; Nomair, A.M.; Osman, A.M.; Nomeir, H.M.; Farag, N.M.
Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines 2022, 10, 2177.
https://doi.org/10.3390/vaccines10122177
AMA Style
Saber MM, Nomair AM, Osman AM, Nomeir HM, Farag NM.
Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines. 2022; 10(12):2177.
https://doi.org/10.3390/vaccines10122177
Chicago/Turabian Style
Saber, Manal Mohamed, Azhar Mohamed Nomair, Ashraf M. Osman, Hanan Mohamed Nomeir, and Naglaa M. Farag.
2022. "Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients" Vaccines 10, no. 12: 2177.
https://doi.org/10.3390/vaccines10122177
APA Style
Saber, M. M., Nomair, A. M., Osman, A. M., Nomeir, H. M., & Farag, N. M.
(2022). Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines, 10(12), 2177.
https://doi.org/10.3390/vaccines10122177